Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Clears GSK For ‘Quick' Trials Of H1N1 Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

India has given its okay for multinational drug maker GlaxoSmithKline to streamline usual procedures and conduct quick trials of an H1N1 flu vaccine in India. The move is expected to make the GSK vaccine available in India by the end of the year, probably as early as December. India's health ministry has ordered 10 million doses of the vaccine if the trials prove successful, a move that encouraged GSK to test the vaccine in the country. The government plans to conduct its own trials simultaneously with GSK's. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts